Special Issue "Hot Topics in Schizophrenia Research"
Deadline for manuscript submissions: 31 March 2021.
Interests: clinical psychiatry; mental illness; psychopathology; psychotherapeutic processes
Interests: neuroscience; psychopathology; memory; neuroimaging; cognitive neuroscience; mental illness
Schizophrenia represents neurodevelopmental disorders and is ranked among most substantial causes of disability worldwide. It is characterized by multidimensional psychopathology that includes positive, negative and mood symptoms as well as cognitive impairment. The etiology of schizophrenia is even more complex with the involvement of several genetic and environmental factors. Although heritability rates of schizophrenia exceed 80% in twin studies, rare variants with large effect size estimates can be detected in the minority of patients with schizophrenia. Similarly, several environmental exposures have been associated with schizophrenia risk and include, i.e., early-life infections, obstetric complications, psychosocial stress and substance use. However, none of them is neither necessary nor sufficient for the development of schizophrenia. Antipsychotic drugs are still perceived as the main treatment of schizophrenia. Although they largely improve a severity of positive symptoms, their efficacy with respect to negative symptomatology and cognitive deficits is insufficient. Additionally, adverse metabolic effects of antipsychotics contribute to cardiovascular comorbidity that is highly prevalent in patients with schizophrenia. The aim of this special issue is to provide a forum of review papers and original studies that address hot topics related to the etiology and emerging treatments of schizophrenia-spectrum disorders.
Dr. Andreas Reif
Dr. Blazej Misiak
Dr. Jerzy Samochowiec
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Severe mental illness
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Pathophysiology and treatment of cognitive dysfunction in schizophrenia
Abstract: Pervasive cognitive impairments across a wide range of domains is a core feature of schizophrenia (SZ). Cognitive dysfunction is an important determinant of long-term functional outcome in SZ and its treatment continues to represents a major challenge. Effective treatment is impeded by our limited knowledge about the underlying pathophysiological mechanisms. This review will discuss current approaches to elucidate pathophysiological mechanisms underlying cognitive dysfunction in SZ. We will outline how complementary strategies derived from basic research and cognitive neuroscience can pave the way to the development of innovative pharmacological and non-pharmacological treatments based on neuromodulatory, neuroprotective and neuroplastic mechanisms.
Title: Systematic review of receptor binding properties of novel antipsychotics (lumateperone, cariprazine, lurazidone, brexpiprazole) - clinically oriented comparison
Title: A systematic review of the relationships between cognitive biases related to psychosis and its risk states: in what direction should go future studies